GlobeNewswire 2024-02-26 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 2024-02-22 argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29,...
GlobeNewswire 2024-02-20 argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review f...
GlobeNewswire 2024-02-14 Genmab Publishes 2023 Annual Report
GlobeNewswire 2024-01-18 argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcu...
GlobeNewswire 2024-01-08 argenx Highlights 2024 Strategic Priorities
GlobeNewswire 2024-01-02 argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 2023-12-07 TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commerci...
GlobeNewswire 2023-11-28 argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocyt...
GlobeNewswire 2023-11-16 argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Gene...
GlobeNewswire 2023-11-13 RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire 2023-11-09 X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 2023-11-07 Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates
GlobeNewswire 2023-11-01 RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
GlobeNewswire 2023-11-01 argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scie...
GlobeNewswire 2023-11-01 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 2023-10-31 argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
GlobeNewswire 2023-10-24 argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
GlobeNewswire 2023-10-18 X4 Pharmaceuticals Announces Appointment of Industry Veteran R. Keith Woods to Board of Directors
GlobeNewswire 2023-09-21 argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized M...
GlobeNewswire 2023-09-18 Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injec...
GlobeNewswire 2023-09-15 argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Grav...
GlobeNewswire 2023-08-30 argenx to Present at Upcoming Investor Conferences
GlobeNewswire 2022-03-28 argenx announces closing of global offering
GlobeNewswire 2022-03-24 argenx raises $700 million in gross proceeds in a global offering